Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer

NCT00905021 is registered in ClinicalTrials.gov with Baylor Breast Care Center as lead sponsor.

NCT NCT00905021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00905021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer
Lead sponsor
Baylor Breast Care Center
Phase
Phase 1/2
Overall status
Terminated
Start date
March 31, 2010
Completion date
February 29, 2012
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer